

ISR Vaccine AB has now completed the in vivo part of the toxicology study for the SARS-CoV-2 vaccine

ISR Vaccine AB has now completed the in vivo part of the toxicological program for the company's SARS-CoV-2 vaccine candidate without any side effects being noted. Analysis of blood and tissues is ongoing according to plan.

“The results so far support that our vaccine candidate is safe and behaves as expected. We are now waiting for the pathology and blood tests before the analysis and report can be completed”.

Comments Ola Winqvist, CEO of ISR

The results of the Toxicology study will be a central part of the application to the Bangladesh Pharmaceutical Agency (BMRC) for conducting a clinical study. Following an approved application from the BMRC and the ethics committee, ISR's spike-based vaccine candidate will be evaluated in a phase I / II double-blind placebo-controlled multicenter study where safety, dose, route of administration, immunogenicity and efficacy are evaluated. In this study, 90 healthy participants are planned to be included for nasal application.

For further information, please contact:

Ola Winqvist

CEO, ISR Immune System Regulation Holding AB (publ)

E-post: ola.winqvist@israb.se

Phone: +46 (0)70 5427939

About ISR Immune System Regulation Holding AB (publ)

ISR is an innovation driven pharmaceutical development company within immunotherapy. The company focuses on clinical and preclinical research, with the goal to develop a broad-spectrum antiviral platform of immune regulating pharmaceuticals. Mangold is the company's Certified Adviser, and can be reached on phone +46 (0)8-463 80 00.

www.israb.se

This information is subject to compulsory publication by Immune System Regulation Holding AB (publ) complying with EU's Market Abuse Regulation (MAR), and the Market Abuse Act